Daiichi Sankyo Korea has signed an agreement with Daewoong to co-promote Ollomax, the latter's hypertension and hyperlipidemia treatment, starting from May.

Under the accord, the two companies will jointly promote and market the treatment at hospitals that have 100 beds or more.

The treatment is the third locally developed product that Daiichi Sankyo Korea has included in its portfolio, following the Daewoong's Olostar and Kunil Pharmaceutical's Omacorm. The collaboration is due to the company's "Partner of Choice" strategy, which aims to expand the portfolio and maintain expertise by recognizing the academic promotion capacity accumulated in the cardiovascular field.

Daiichi Sankyo Korea and Daewoong Pharmaceutical have established a partnership in the cardiovascular field, starting with Daewoong's Olmesartan family and the Daiichi Sankyo's Lixiana. The two companies expect that the expertise and strategic co-promotion experience gained through such a partnership will help them gain trust from patients and medical staffs.

"We are very pleased to co-promote Daewoong Pharmaceutical's Ollomax," said Yang Gil-dong, head of marketing at Daiichi Sankyo Korea.

The company expects that it will be able to strengthen its cardiovascular portfolio through the introduction of Ollomax, and will try to make more patients benefit from treatment, he added.